Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.

Polaprezinc noninferior to rebamipide as add-on to PPI for treating ulcer following ESD

17 May 2020

In patients with endoscopic submucosal dissection (ESD)-induced ulcer, the combination of polaprezinc plus proton pump inhibitor (PPI) promotes healing as effectively as rebamipide plus PPI, as shown in a study.

Although widely used to treat gastric neoplasms, ESD causes large and deep artificial ulcers, researchers said, adding that there are no guidelines with regard to the optimal treatment durations and drug regimens for ESD-induced ulcers.

A total of 210 patients who had developed ulcer following ESD were randomized to receive treatment with either polaprezinc (150 mg/d) or rebamipide (300 mg/d) in addition to pantoprazole (40 mg/d). Researchers used χ2 or Fisher exact test and the Student t test to evaluate ulcer healing rate and its condition at 4 weeks after dissection.

Polaprezinc showed noninferiority to rebamipide in terms of ulcer healing rate 4 weeks following ESD both in the intention-to-treat analysis (90.3 percent vs 91.4 percent, respectively; p=0.523) and per-protocol analysis (89.9 percent vs 91.1 percent, respectively; p=0.531).

A short procedure time independently predicted a high ulcer healing rate (odds ratio, 0.975, 95 percent confidence interval, 0.958–0.993; p=0.006).

Polaprezinc is an antiulcer agent that inhibits proinflammatory cytokine-induced NF-κB activation and interleukin-8 expression in gastric epithelial cells, promoting ulcer healing. The drug is commonly prescribed for gastric ulcers in Japan. [Biol Trace Elem Res 2014;158:280-288]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.